GlobeNewswire by notified

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Share

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Paris, France, November 20, 2023 – 5:45 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, whose safeguard proceedings (procédure de sauvegarde) were converted into receivership (redressement judiciaire) by decision of the Paris Commercial Court on November 13, 2023, announces that the court-appointed administrators have today received a takeover offer for the assets and activities of Pixium.

The date for the hearing to examine the takeover offer will be set by the Commercial Court by the end of November.

The Company draws investors’ attention to the fact that, given the current offer and the Company’s level of indebtedness, the sale proceeds received in the context of the Company’s insolvency proceedings do not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Innofactor Plc: Share Repurchase 7.12.20237.12.2023 17:30:00 CET | Press release

Innofactor Plc Announcement 7.12.2023Innofactor Plc: Share Repurchase 7.12.2023In the Helsinki Stock ExchangeTrade date 7.12.2023Bourse trade BuyShare IFA1VAmount 4,500SharesAverage price/ share 1.1494EURTotal cost 5,172.30EURInnofactor Plc now holds a total of 575 629 sharesincluding the shares repurchased on 7.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comwww.innofactor.com Attachment Innofactor_7.12_trades

Coloplast A/S - Skift af revisor7.12.2023 17:29:40 CET | pressemeddelelse

I dag, den 7. december 2023, har Coloplast A/S afholdt ordinær generalforsamling, hvor EY Godkendt Revisionspartnerselskab blev valgt som Coloplast A/S’ revisor i overensstemmelse med forslaget fra bestyrelsen. For yderligere information, kontakt venligst Investorer og analytikere Anders Lonning-Skovgaard Koncerndirektør, CFO Tlf. 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tlf. 4911 1800 / 4911 2458 E-mail: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor Relations Tlf. 4911 1800 / 4911 3266 E-mail: dkkhu@coloplast.com Presse og medier Peter Mønster Sr. Media Relations Manager Tlf. 4911 2623 Email: dkpete@coloplast.com Adresse Coloplast A/S Holtedam 1 3050 Humlebæk Danmark CVR Nr. 69749917 Hjemmeside www.coloplast.com Denne selskabsmeddelelse foreligger på dansk og engelsk. I tvivlstilfælde er den engelske version gældende. Coloplast blev grundlagt på passion, ambition og engagement. Vi opstod på grundlag af en sygeplejerskes ønske om at hjælpe

Coloplast A/S - Change of auditor7.12.2023 17:29:40 CET | Press release

Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S’ auditors in line with the proposal from the Board of Directors. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: dkkhu@coloplast.com Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and comm

Coloplast A/S - Articles of Association7.12.2023 17:26:55 CET | Press release

Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: dkkhu@coloplast.com Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the

Coloplast A/S - Vedtægter7.12.2023 17:26:55 CET | pressemeddelelse

Vedlagt er vedtægter for Coloplast A/S som vedtaget på Coloplast A/S’ ordinære generalforsamling afholdt i dag den 7. december 2023. For yderligere information, kontakt venligst Investorer og analytikere Anders Lonning-Skovgaard Koncerndirektør, CFO Tlf. 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tlf. 4911 1800 / 4911 2458 E-mail: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor Relations Tlf. 4911 1800 / 4911 3266 E-mail: dkkhu@coloplast.com Presse og medier Peter Mønster Sr. Media Relations Manager Tlf. 4911 2623 Email: dkpete@coloplast.com Adresse Coloplast A/S Holtedam 1 3050 Humlebæk Danmark CVR Nr. 69749917 Hjemmeside www.coloplast.com Denne selskabsmeddelelse foreligger på dansk og engelsk. I tvivlstilfælde er den engelske version gældende. Coloplast blev grundlagt på passion, ambition og engagement. Vi opstod på grundlag af en sygeplejerskes ønske om at hjælpe sin søster og en ingeniørs faglige evner. Vi er drevet af empati, og vores mis